Wells Fargo Upgrades Apellis to Overweight - $32 Price Target
Wells Fargo raises Apellis to Overweight with $32 target, citing stable Syfovre sales and strong Empaveli launch potential. Stock could gain 15-20%.
Already have an account? Sign in.